It would be very interesting to evaluate the use of 46F2SIP/L19-IL2 combined therapy in an orthotopic xenograft model of ovarian carcinoma via intraperitoneally injection of ovarian carcinoma cells derived from EOC patients to recapitulate, in part, the patterns of growth and metastasis seen in patients. This evidence concerns the gene IL2 and ovarian carcinoma.